Variation in geographical treatment intensity affects survival of non-small cell lung cancer patients in England

被引:21
|
作者
Tataru, Daniela [1 ]
Spencer, Katie [2 ]
Bates, Andrew [3 ]
Wieczorek, Andrzej [4 ]
Jack, Ruth H. [1 ]
Peake, Michael D. [1 ,5 ,6 ]
Lind, Michael J. [4 ,7 ]
Luchtenborg, Margreet [1 ,8 ]
机构
[1] Publ Hlth England, Natl Canc Registrat & Anal Serv, Wellington House,133-155 Waterloo Rd, London SE1 8UG, England
[2] Univ Leeds, Fac Med & Hlth, Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England
[3] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England
[4] Hull & East Yorkshire NHS Trust, Kingston Upon Hull, N Humberside, England
[5] Univ Leicester, Inst Lung Hlth, Leicester, Leics, England
[6] Univ Coll London Hosp, Ctr Canc Outcomes, London, England
[7] Univ Hull, Hull York Med Sch, Kingston Upon Hull, N Humberside, England
[8] Kings Coll London, Fac Life Sci & Med, Div Canc Studies, Dept Canc Epidemiol Populat & Global Hlth, London, England
关键词
Non-small cell lung cancer; Curative treatment; Surgical resection; Radical radiotherapy; Geographical variation; England; RESECTION; UK; RADIOTHERAPY; MANAGEMENT; TRENDS;
D O I
10.1016/j.canep.2018.09.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: We aimed to determine the geographical variation in the proportion of non-small cell lung cancer (NSCLC) patients undergoing curative treatment and assess the relationship between treatment access rates and survival outcomes. Methods: We extracted cancer registration data on 144,357 lung cancer (excluding small cell tumours) patients diagnosed between 2009 and 2013. Surgical and radiotherapy treatment intensity quintiles were based on patients' Clinical Commissioning Group (CCG) of residence. We used logistic regression to assess the effect of travel time and case-mix on treatment use and Cox regression to analyse survival in relation to treatment intensity. Results: There was wide variation in the use of curative treatment across CCGs, with the proportion undergoing surgery ranging from 8.9% to 20.2%, and 0.4% to 16.4% for radical radiotherapy. The odds of undergoing surgery decreased with socioeconomic deprivation (OR 0.91, 95% CI 0.85-0.97), whereas the opposite was observed for radiotherapy (OR 1.16, 95% CI 1.08-1.25). There was an overall effect of travel time to thoracic surgery centre on the odds of undergoing surgery (OR 0.81, 95% CI 0.76-0.87 for travel time > 55 min vs <= 15 min) which was amplified by the effect of deprivation. No clear association was observed for radiotherapy. Higher mortality rates were observed for the lower resection and radiotherapy quintiles (HR 1.08, 95% CI 1.04-1.12 and HR 1.06, 95% CI 1.02-1.10 for lowest vs. highest resection and radiotherapy quintile). Conclusion: There was wide geographical variation in the use of curative treatment and a higher frequency of treatment was associated with better survival.
引用
收藏
页码:13 / 23
页数:11
相关论文
共 50 条
  • [41] Trends in Survival Based on Treatment Modality in Non-Small Cell Lung Cancer Patients: A Population-Based Study
    Akhtar-Danesh, Noori
    Akhtar-Danseh, Gileh-Gol
    Seow, Hsien Yeang
    Shakeel, Saad
    Finley, Christian
    CANCER INVESTIGATION, 2019, 37 (08) : 355 - 366
  • [42] The Impact of Serum EGFR Levels on Survival of Resected Patients with Non-Small Cell Lung Cancer
    Hekimoglu, Elvin
    Oltulu, Yasemin
    Yaylim, Ilhan
    Kaynak, Kamil
    Turna, Akif
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S286 - S286
  • [43] The effects of radiotherapy on the survival of patients with unresectable non-small cell lung cancer
    Tini, Paolo
    Nardone, Valerio
    Pastina, Pierpaolo
    Pirtoli, Luigi
    Correale, Pierpaolo
    Giordano, Antonio
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (06) : 593 - 602
  • [44] Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer
    Luciani, A.
    Bertuzzi, C.
    Ascione, G.
    Di Gennaro, E.
    Bozzoni, S.
    Zonato, S.
    Ferrari, D.
    Foa, P.
    LUNG CANCER, 2009, 66 (01) : 94 - 96
  • [45] Solitary metastasectomy in non-small cell lung cancer
    Karagkiouzis, G.
    Koulaxouzidis, G.
    Tomos, P.
    Spartalis, E. D.
    Konstantinou, F.
    Charpidou, A.
    Syrigos, K. N.
    JOURNAL OF BUON, 2012, 17 (04): : 712 - 718
  • [46] Medical Treatment in Elderly Patients with Non-Small Cell Lung Cancer
    Kamila Bakirhan
    Janaki Sharma
    Roman Perez-Soler
    Haiying Cheng
    Current Treatment Options in Oncology, 2016, 17
  • [47] Medical Treatment in Elderly Patients with Non-Small Cell Lung Cancer
    Bakirhan, Kamila
    Sharma, Janaki
    Perez-Soler, Roman
    Cheng, Haiying
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (03)
  • [48] CRIZOTINIB FOR THE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Bowles, D. W.
    Weickhardt, A. J.
    Doebele, R. C.
    Camidge, D. R.
    Jimeno, A.
    DRUGS OF TODAY, 2012, 48 (04) : 271 - 282
  • [49] Surgical outcomes of patients with non-small cell lung cancer following neoadjuvant treatment
    Ocakcioglu, Ilhan
    Alpay, Levent
    Ermerak, Nezih Onur
    Kiral, Hakan
    Tezel, Cagatay
    Baysungur, Volkan
    Yalcinkaya, Irfan
    MARMARA MEDICAL JOURNAL, 2018, 31 (03): : 101 - 107
  • [50] Pulmonary Rehabilitation in Non-small Cell Lung Cancer Patients After Completion of Treatment
    Glattki, Georg P.
    Manika, Katerina
    Sichletidis, Lazaros
    Alexe, Gabriela
    Brenke, Rainer
    Spyratos, Dionisios
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (02): : 120 - 125